Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
نویسندگان
چکیده
Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411-£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted life year (QALY) during DRMM was £66,983. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM.
منابع مشابه
Assessment of Real-World Treatment Patterns and Outcomes In Relapsed or Refractory Multiple Myeloma: Evidence From A Brief Multi-Country Survey of European Physicians.
Assessment of Real-World Treatment Patterns and Outcomes in Relapsed or Refractory Multiple Myeloma: Evidence From a Brief Multicountry Survey of European Physicians Keith L Davis, Huamao Mark Lin, Ai-Min Hui, Shumin Zhang, James A Kaye RTI Health Solutions, Research Triangle Park, NC, United States; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Li...
متن کاملClinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first-in-class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen for daratumumab is challenging due to its target-mediated drug disposition, leading to time- and co...
متن کاملUpfront Overall Survival Modelling in Comparison to Real World Data: Lenalidomide for the Treatment of Multiple Myeloma Patients in South Korea.
Decision makers are frequently faced with the question of how realistic are cost-effectiveness models. Overall survival (OS) is a desired clinical trial and health technology assessment endpoint but frequently unrealistic or elusive at the point of new drugs financing decision. We aim to compare the overall survival from lenalidomide treatment in relapsed/refractory multiple myeloma (rrMM) pati...
متن کاملTreatment Sequencing Patterns And Costs of Care in Patients with Relapsed/Refractory Multiple Myeloma.
N N Multiple myeloma (MM) is a cancer of plasma cells of the bone marrow, and the 5-year survival rate among patients with MM is 45%. N N Treatment practices are changing rapidly, with novel agents and stem cell transplantation now recommended for MM treatment. N N An analysis of data from 1999–2007 found that use of traditional chemotherapies has decreased substantially in the US, while use of...
متن کاملImproved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
INTRODUCTION Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma (MM). Efficacy and safety of bortezomib is well known; however, it was necessary to validate the data in patients with different ethnic backgrounds. The efficacy and safety of bortezomib was assessed in patients from China with relapsed/refractory MM in a real-world scenario. METH...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 10 شماره
صفحات -
تاریخ انتشار 2015